N-sulphonylated amino acid derivatives, method for the production and use thereof

Patent Citations (14)

Non-Patent Literature (29)

• Wilhelm et al. “preparation and use . . . ” CA 132:108297 (2000).Examiner
• Wilkstroem et al. “prparation of 2-amidino . . . ” CA 132:222869 (2000).Examiner
• Renatus et al. “Structural and functional . . . ” J. Med. Chem. v.41, p. 5445-5456 (1998).Examiner
• Rubini et al. “Synthesis of isosteri . . . ” Tetrhedron v. 42, p. 6039-6045 (1986).Examiner
• Patani et al. “Bioisosterism . . . ” Chem. Rev. v.96, p. 3147-3148, 3170 (1996).Examiner
• Stuerzebecher et al. “Piperazine of . . . ” CA 122:161363 (1995).Examiner
• Coussens et al., “Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations,” Science 295:2387-2392 (2002).Applicant
• Dexter et al., “N,N-Dimethylformamide-Induced Alteration of Cell Culture Characteristics and Loss of Tumorigenicity in Cultured Human Colon Carcinoma Cells,” Cancer Research 39:1020-1025 (1979).Applicant
• Dixon et al., “The Determination of Enzyme Inhibitor Constants,” Biochem J. 55:170-171 (1953).Applicant
• Enyedy et al., “Structure-Based Approach for the Discovery of Bis-Benzamidines as Novel Inhibitors of Matriptase,” J. Med. Chem. 44:1349-1355 (2001).Applicant
• Friedrich et al., “Catalytic Domain Structures of MT-SP1/Matriptase, a Matrix-Degrading Transmembrane Serine Proteinase,” The Journal of Biological Chemistry 277:2160-2168 (2002).Applicant
• Hooper et al., “Type II Transmembrane Serine Protease,” The Journal of Biological Chemistry 276:857-860 (2001).Applicant
• Ihara et al., “Prometastatic Effect of N-Acetylglucosaminyltransferase V is Due to Modification and Stabilization of Active Matriptase by Adding β1-6 GIcNAc Branching,” The Journal of Biological Chemistry 277:16960-16967 (2002).Applicant
• Kang et al., Tissue Microarray Analysis of Hepatocyte Growth Factor/Met Pathway Components Reveals a Role for Met, Matriptase, and Hepatocyte Growth Factor Activator Inhibitor 1 in the Progression of Node-negative Breast Cancer, Cancer Research 63:1101-1105 (2003).Applicant
• Lee et al., “Activation of Hepatocyte Growth Factor and Urokinase/Plasminogen Activator by Matriptase, an Epithelial Membrane Serine Protease,” The Journal of Biological Chemistry 275:36720-36725 (2000).Applicant
• Lin et al., “Purification and Characterization of a Complex Containing Matriptase and a Kunitz-type Serine Protease Inhibitor from Human Milk,” The Journal of Biological Chemistry 274:18237-18242 (1999).Applicant
• Lin et al., “Molecular Cloning of cDNA for Matriptase, a Matrix-Degrading Serine Protease with Trypsin-Like Activity,” The Journal of Biological Chemistry 274:18231-18236 (1999).Applicant
• Lin et al., “Characterization of a Novel, Membrane-bound, 80-kDa Matrix-Degarding Protease From Human Breast Cancer Cells,” The Journal of Biological Chemistry 272:9147-9152 (1997).Applicant
• Long et al., “Synthesis and Evaluation of the Sunflower Derived Trypsin Inhibitor as a Potent Inhibitor of the Type II Transmembrane Serine Protease, Matriptase,” Biorganic & Medicinal Chemistry Letters 11:2515-2519 (2001).Applicant
• Oberst et al., “Expression of the Serine Protease Matriptase and Its Inhibitgor HAI-I in Epithelial Ovarian Cancer: Correlation with Clinical Outcome and Tumor Clinicopathological Parameters,” Clinical Cancer Research 8:1101-1107 (2002).Applicant
• Shi et al., “Identification and Characterization of a Novel Matrix-Degrading Protease from Hormone-Dependent Human Breast Cancer Cells,” Cancer Research 53:1409-1415 (1993).Applicant
• Stürzebecher et al., “3-Amidinophenylalanine-Based Inhibitors of Urokinase,” Bioorganic & Medicinal Chemistry Letters 9:3147-3152 (1999).Applicant
• Sucker et al., “Pharmazeutische Technologie,” Georg Thieme Verlag Stuttgart, New York, 1991.Applicant
• Takeuchi et al., “Reverse Biochemisty: Use of Macromolecular Protease Inhibitors to Dissect Complex Biological Processes and Identify a Membrane-Type Serine Protease in Epithelial Cancer and Normal Tissue,” Proc. Natl. Acad. Sci. 96:11054-11061 (1999).Applicant
• Takeuchi et al., “Cellular Localization of membrane-Type Serine Protease 1 and Identification of Protease-Activated Receptor-2 and Single chain Urokinase-Type Plasminogen Activator as Substrates,” The Journal of Biological Chemistry 275:26333-26342 (2000).Applicant
• Zeslawska et al., “Crystals of the Urokinase Type Plasminogen Activator Variant βc-uPA in Complex with Small Molecule Inhibitors Open the Way towards Structure-Based Drug Design,” J. Mol. Boil. 301:465-475 (2000).Applicant
• Zhang et al., “Assignment of Human Putative Tumor Suppressor Genes ST13 (Alias SNC6) and ST14 (Alias SNC19) to Human Chromosome Bands 22q13 and 11q24 →q25 by in Situ Hybridization,” Cytogenet Cell Genet 83:56-57 (1998).Applicant
• Bauer, “Hilfsstoffe,” in Pharmazeutische Technologie. Sucker et al. (eds.), Georg Thieme Verlag Stuttgart: New York, p. 174-216 (1991).Applicant
• Hooper et al., “Type II Transmembrane Serine Proteases,” J. Biol. Chem. 276:857-860 (2001).Applicant